UnitedHealth Group reported robust Q2 results with $112 billion in revenue and adjusted EPS of $6.38, showing significant margin improvements in both UnitedHealthcare and Optum Health segments. The company’s operational turnaround is driven by cost controls, contract resets, and technology efficiencies, leading to sustainable margin expansion. Medicare Advantage profitability is recovering due to improved pricing and care management, supporting earnings growth expected through 2027 and 2028. Trading below its historical P/E with a 2.46% dividend yield and ongoing buybacks, UnitedHealth offers an attractive risk-reward profile for investors.
UnitedHealth Group shares are trading at USD 378.12 on Pluang as of Sep 22, 2026 19:02 WIB, showing a modest 0.15% gain in the last day. The stock maintains a dividend yield of 2.46%, consistent with the article's mention. Investor interest remains strong with 94% of Pluang orders on the buy side, reflecting confidence in the company's earnings growth outlook.
